Status:
COMPLETED
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab an...
Eligibility Criteria
Inclusion
- Histologic or cytologic confirmation of select incurable solid malignancies that are advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
- Available tumor tissue for biomarker analysis
- Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
Exclusion
- Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease
- History of interstitial lung disease / pneumonitis
- Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
- Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
May 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 19 2025
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT03459222
Start Date
May 30 2018
End Date
February 19 2025
Last Update
April 2 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0006
Duarte, California, United States, 91010
2
Local Institution - 0003
Aurora, Colorado, United States, 80045
3
Local Institution - 0004
Baltimore, Maryland, United States, 21231
4
Local Institution - 0005
St Louis, Missouri, United States, 63110